Neurosant Therapeutics

Neurosant treats neurologic disease such as Smith-Magenis Syndrome caused by loss of dosage-sensitive genes, untreatable by current gene therapy technologies.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Diego, CA, USA
  • Currency USD
  • Founded February 2020
  • Employees 1
  • Incorporation Type Not Incorporated

Company Summary

Neurosant’s lead compounds have the demonstrated ability to correct the underlying cause of Smith Magenis Syndrome (SMS). Currently, only palliative care is available. With over 56,000 patients (US and EU) and over 500,000 patients worldwide, peak sales in the USA will exceed $1B per year. With a 4 yr. exit strategy, valuation of over $500M, Neurosant seeks $500K to advance our repurposed lead compound to a development candidate for SMS.

Team

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free